Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02868996
Other study ID # DM199-2016-001
Secondary ID
Status Completed
Phase Phase 1
First received August 8, 2016
Last updated December 5, 2017
Start date September 2016
Est. completion date March 2017

Study information

Verified date December 2017
Source DiaMedica USA Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in healthy volunteers. The study will be consist of two parts: Part A will focus on intravenous dosing and Part B will directly compare intravenous dosing with subcutaneous dosing.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date March 2017
Est. primary completion date March 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Male or female between 18 and 50 years of age (inclusive);

2. Healthy with no clinically significant medical problems;

3. BMI between 18 to 30 kg/m2 with a weight between 50 to 100 kg (both inclusive);

4. No history of alcohol or drug abuse (Paracetamol, Barbiturates, Benzodiazepines, Cocaine, Methadone, Amphetamines, Methamphetamines, Opiates, Phencyclidine, Tetrahydrocannabinol (cannabis), Tricyclic Antidepressants). Subjects should be enrolled only after passing the urine drug screen (positive test for paracetamol will be allowed);

5. Non-smokers or light smokers (Less than 5 cigarettes per day) by history and planned during the study;

6. No history of significant allergic diathesis such as urticaria, angioedema or anaphylaxis;

7. Receiving no chronic medications that affect blood pressure control, the bradykinin or angiotensin system including angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB);

8. Willing and able to sign written, informed consent.

Exclusion Criteria:

1. Any significant past or current cardiac, pulmonary, hepatic, renal or other medical condition which in the opinion of the investigator would make participation of the subject in this study medically unsafe or compromise the accuracy of assessment of safety, pharmacokinetic and pharmacodynamic data of the study;

2. Subjects who have abnormal safety labs outside the local lab ranges will be excluded at PI's discretion based on his/her assessment of clinical significance (can be repeated once at screening at PI's discretion);

3. Subjects with past medical history of malignancy except basal cell or squamous cell carcinoma of the skin who have had curative surgical treatment and at least 6 months have elapsed since the procedure;

4. A value outside the specified range of 90 mm Hg - 140 mm Hg for systolic blood pressure and 50 mm Hg - 90 mm Hg for diastolic blood pressure (both inclusive) at screening (can be repeated once at screening as per PI's discretion);

5. Subjects using angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) to control blood pressure;

6. History of clinically significant acute bacterial, viral, or fungal systemic infections in the last 4 weeks prior to screening;

7. Clinical or laboratory evidence of an active infection at the time of screening;

8. Known alpha 1-antitrypsin deficiency (a1-antitrypsin deficiency);

9. Serological evidence of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (Anti-HCV) at screening;

10. Vaccination within 3 months of screening for the study or requiring vaccination during the study or within 3 months after completion of the study;

11. Females who are pregnant or nursing;

12. Females of childbearing potential (i.e., any woman who is not surgically sterile e.g., hysterectomy, bilateral oophorectomy or >1-year postmenopause status confirmed by follicle-stimulating hormone (FSH) levels as defined by established lab ranges) and all men who, if participating in heterosexual sexual activity that could lead to pregnancy are unable or unwilling to practice medically effective contraception during the study. They should agree to use two reliable methods of contraception (e.g., double-barrier condom plus diaphragm, condom or diaphragm plus a stable dose of hormonal contraception) throughout the study period and until 3 months after receiving study drug. Women of childbearing potential will require compulsory pregnancy testing. A negative pregnancy test (serum and urine) will be documented during screening and at Day -1 respectively;

13. Participation in any other drug study within 8 weeks or 5 half-lives of the study drug, whichever is longer;

14. Unable or unwilling to comply with the protocol requirements for study visits and procedures;

15. Subjects who do not have good venous access for infusion of study drug or for blood sampling;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Recombinant human tissue kallikrein
Intravenous DM199

Locations

Country Name City State
Australia Linear Clinical Research Perth Western Australia

Sponsors (2)

Lead Sponsor Collaborator
DiaMedica USA Inc. Novotech (Australia) Pty Limited

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Assessment of safety of intravenous dosing 30 days
Secondary Concentration of DM199 in plasma Assess plasma drug levels 3 days
Secondary Concentration of bradykinin in plasma Assess drug associated biomarkers (e.g. plasma bradykinin levels) 3 days
See also
  Status Clinical Trial Phase
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT03281590 - Stroke and Cerebrovascular Diseases Registry N/A
Recruiting NCT03402906 - Family-Clinician Collaboration to Improve Neglect and Rehabilitation Outcome After Stroke N/A
Recruiting NCT03305731 - Activating Behavior for Lasting Engagement After Stroke N/A
Recruiting NCT02822144 - General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke Phase 3
Active, not recruiting NCT03371290 - Acute Effect of Mirror Therapy on Rehabilitation of Paretic Upper Extremity After Chronic Stroke N/A
Recruiting NCT03294187 - Encouragement-induced Movement Therapy in Daily Life N/A
Enrolling by invitation NCT03259373 - IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation N/A
Enrolling by invitation NCT03314818 - Natural History of Carotid Plaque as Determined by 3D Ultrasound N/A
Recruiting NCT02911129 - Effects of Prism Adaption and rTMS on Brain Connectivity and Visual Representation N/A
Not yet recruiting NCT03259932 - Comparison of Fatigue and Recovery After Stroke Depending on the Usual Management With or Without Physical Training N/A
Not yet recruiting NCT03298243 - Use of Sensory Substitution to Improve Arm Control After Stroke N/A
Not yet recruiting NCT03274505 - Sleep Disorders in Transient Ischemic Attack and Stroke: SOMN'AIC Study N/A
Not yet recruiting NCT03177954 - Developing a Patient Oriented Discharge Summary for Stroke Inpatients N/A
Recruiting NCT03080454 - The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke N/A
Recruiting NCT03025776 - One vs. Two Hand Use After Stroke: Role of Task Requirements N/A
Recruiting NCT02916030 - Vitamin D and Stroke N/A
Recruiting NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction N/A